Pharmacological characteristics and clinical study results of ileal bile acid transporter inhibitor elobixibat (GOOFICE<sup>®</sup> tablet 5 mg)
Naoki Ikeda(EA Pharma (Japan)), Mitsunori Seki(EA Pharma (Japan)), Shinya Taniguchi(Konan University)
Cited by 1
Related Papers
Safety and efficacy of elobixibat for chronic constipation: results from a randomised, double-blind, placebo-controlled, phase 3 trial and an open-label, single-arm, phase 3 trial
|The Lancet. Gastroenterology & hepatology|2018|174
Olmesartan Is an Angiotensin II Receptor Blocker with an Inhibitory Effect on Angiotensin-Converting Enzyme
|Hypertension Research|2006|135
A Homologue ofN-Ethylmaleimide-sensitive Factor in the Malaria ParasitePlasmodium falciparum Is Exported and Localized in Vesicular Structures in the Cytoplasm of Infected Erythrocytes in the Brefeldin A-sensitive Pathway
|Journal of Biological Chemistry|2001|72
Determining an optimal clinical dose of elobixibat, a novel inhibitor of the ileal bile acid transporter, in Japanese patients with chronic constipation: a phase II, multicenter, double-blind, placebo-controlled randomized clinical trial
|Journal of Gastroenterology|2017|62
QT PRODACT: A Multi-site Study of In Vitro Action Potential Assays on 21 Compounds in Isolated Guinea-Pig Papillary Muscles
|Journal of Pharmacological Sciences|2005|46